How FDA Should Use Its Authority to Regulate Human Cells
FDA should encourage states to be the primary regulators of stem cell procedures.
Week in Review
Senate votes against banning mandatory arbitration in financial contracts, House passes a bill to curb “sue and settle” practices, and more…
The Secretary of Energy’s Tariff Proposal Would Be Disastrous
Revising FERC’s open access tariff rules would reverse 40 years of progress.
Curbing Prescription Opioid Abuse Through Insurance Regulation
New study shows regulators have overlooked insurers in tackling the opioid epidemic.
Do Shareholders Actually Have “Contracts” with Delaware Corporations?
Legal scholar argues that Delaware’s longstanding use of contract metaphor should be fixed.
Regulatory Reform Should Be About Strengthening Legislative Responsibility
Countries like Australia and Canada offer models for reining in delegation of lawmaking authority to agencies.
Week in Review
Courts strike down latest version of travel ban, EPA ends “sue and settle” practices, and more…
Does the Administrative State Threaten U.S. Democracy?
Panel focuses on claims of potential dangers from growth in government agencies.
FDA’s Authority to Regulate Off-Label Promotion
Expert argues that federal law gives regulator authority to restrict unauthorized drug uses.
How the Clean Power Plan’s Repeal Undermines Regulatory Analysis
The Trump Administration’s purported economic justification weakens the credibility of cost-benefit analysis.
Building for Disaster
Data show that more stringent building codes deliver benefits greatly exceeding their costs.
Week in Review
EPA announces repeal of the Clean Power Plan, President Trump signs an EO to provide “Obamacare relief,” and more…